Similar Articles
61 Hepatocellular carcinoma resistance to tyrosine kinase inhibitors: Current status and perspectives
62 Comparing transarterial chemoembolization alone to combined transarterial chemoembolization and radiofrequency ablation in primary hepatocellular carcinoma treatment
63 MEX3A promotes cell proliferation by regulating the RORA/β-catenin pathway in hepatocellular carcinoma
64 Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma
65 Long noncoding RNA semaphorin 6A-antisense RNA 1 reduces hepatocellular carcinoma by promoting semaphorin 6A mRNA degradation
66 Modified LR-5 criteria based on gadoxetic acid can improve the sensitivity in the diagnosis of hepatocellular carcinoma
67 Lung metastasis following temporary discontinuation of lenvatinib and tislelizumab in hepatocellular carcinoma: A case report
68 Neoadjuvant therapy: Dawn of reducing the high post-surgery recurrence rate of hepatocellular carcinoma
69 Progress of research on glucose transporter proteins in hepatocellular carcinoma
70 Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studies
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA